Skip to main content

Table 1 Baseline characteristics of patients

From: Syncope and Epilepsy coexist in ‘possible’ and ‘drug-resistant’ epilepsy (Overlap between Epilepsy and Syncope Study - OESYS)

  Total population (n = 107) Possible Epilepsy (n = 63, 58.9%) Drug- resistant Epilepsy (n = 44, 41.1%)
Mean age, years (mean ± SD, range) 56 ± 21 (18–88) 52 ± 21 (18–88) 62 ± 18 (29–88)
Male gender, n (%) 46 (43.0) 28 (44.4) 18 (40.9)
Heart diseasesa, n (%) 35 (32.7) 13 (20.6) 22 (50.0)
Neurological diseasesb, n (%) 32 (29.9) 22 (34.9) 10 (22.7)
Cardiovascular drugsc, n (%) 46 (43.0) 21 (33.3) 25 (56.8)
Antiepileptic drugsd, n (%) 77 (72.0) 33 (52.4) 44 (100.0)
T-LOC/patient/year (mean ± SD, range) 4 ± 4 (2–20) 3 ± 4 (2–20) 4 ± 4 (2–20)
T-LOC Prodromal symptoms 66 (61.7) 40 (63.5) 26 (59.1)
After T-LOC characteristics
 Involuntary movements 58 (54.2) 37 (58.7) 21 (47.7)
 Mental contusion, n (%) 26 (24.3) 26 (41.3) 12 (27.3)
 Physical injury, n (%) 55 (51.4) 31 (49.2) 24 (54.6)
Comorbidities, n (%)
 Hypertension, n (%) 41 (38.3) 20 (31.7) 21 (47.7)
 Diabetes, n (%) 10 (9.3) 6 (9.5) 4 (9.1)
 Dyslipidemia, n (%) 18 (16.8) 9 (14.3) 9 (20.5)
  1. T-LOC transient loss of consciousness
  2. aIschemic cardiomyopathy, atrial fibrillation, pulmonary embolism, heart failure
  3. bStroke, Parkinson’s disease, dementia, limbic encephalitis, normal pressure hydrocephalus
  4. cDiuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, nitrate, alpha-blockers, beta-blockers, antiarrhythmics, cardiac glycosides
  5. dPhenobarbital, phenytoin, lamotrigine, valproate, levetiracetam, carbamazepine, gabapentin, pregabalin, topiramate, primidone, vigabatrin